FDA approves Itovebi for locally advanced, metastatic breast cancer
The U.S. Food and Drug Administration has approved Itovebi (inavolisib), in combination with palbociclib (Ibrance) and ...
WebMD2d
New Drug Approved for Common Type of Breast Cancer Recurrence
A new breast cancer drug has received quick federal approval after a clinical trial showed it could more than double the time before a common type of breast cancer recurrence worsens.
Buy Rating for Relay Therapeutics: Promising Pipeline and Positive PI3Ka Inhibitor Prospects
H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Relay Therapeutics (RLAY – Research Report) today and set a price target ...
healthandpharma3d
New First-Line Therapy: FDA Approves Itovebi for PIK3CA-Mutated Advanced Breast Cancer
The FDA has approved Genentech’s Itovebi™ (inavolisib) as a targeted therapy for adults with advanced hormone ...
The Pharma Letter3d
The week in pharma: action, reaction and insight – week to October 11
Significant research news last week saw US biotech Scholar Rock release positive new data for its spinal atrophy (SMA) ...
Managed Healthcare Executive3d
MHE Week in Review – No HIV in Breast Milk, RSV and More
Itovebi is approved to treat patients with PIK3CA-mutated HR-positive, HER2 negative metastatic breast cancer in combination ...
BioWorld5d
FDA gives early nod to Genentech’s first-line breast cancer drug
Genentech Inc. didn’t need to wait until Thanksgiving for the U.S. FDA to make up its mind. More than a month ahead of its ...
Managed Healthcare Executive5d
FDA Approves Itovebi for Metastatic Breast Cancer
Itovebi is approved to treat patients with PIK3CA-mutated HR-positive, HER2 negative metastatic breast cancer in combination ...
The American Journal of Managed Care5d
FDA Approves Inavolisib in Locally Advanced, Metastatic Breast Cancer
Patients with endocrine-resistant, HER2-negative, locally advanced or metastatic breast cancer can use the treatment after ...
precisionmedicineonline5d
FDA Approves Genentech's Itovebi Combo for PIK3CA-Mutated Advanced Breast Cancer Patients
In the INAVO120 trial, Itovebi added to Pfizer's Ibrance and fulvestrant doubled progression-free survival versus Ibrance and fulvestrant alone.
Roche gets FDA approval for Itovebi combo therapy for breast cancer
Roche (RHHBY) has received FDA approval for its drug Itovebi in combination with two other drugs for the treatment of breast ...
Pharmaceutical Technology5d
Roche wins first-line approval for PI3K inhibitor combo in breast cancer
The US FDA approved Itovebi in combination with Pfizer’s Ibrance and AstraZeneca’s Faslodex for certain breast cancer ...